PT-141 (Bremelanotide)
Research highlights
- ✓Selective MC4R agonist acting centrally — distinct from PDE5 inhibitors
- ✓Studied for both male and female sexual function research
- ✓CNS-mediated mechanism with peer-reviewed clinical trial data
- ✓Well-characterised pharmacokinetic profile for research applications
Read Carl's plain-English guide: PT-141 (Bremelanotide) on Peptide Carl ›
What is PT-141?
PT-141 (Bremelanotide) is a melanocortin receptor agonist that acts centrally via MC4R to influence sexual arousal. Unlike PDE5 inhibitors, it works through the CNS rather than vascular pathways, making it a unique research compound.
What purity is guaranteed?
Where we hold an independent Janoshik report for a compound we publish it in full - batch number, purity and a verification key you can check against the lab yourself. Where we do not hold one the product is marked research grade and we say so, rather than claim a report we cannot produce.
PT-141 (Bremelanotide), explained
The short version: PT-141 is bremelanotide, a ring-shaped peptide that switches on melanocortin receptors, including ones in the brain. It is approved in the US as Vyleesi (2019) for low sexual desire in premenopausal women, and that approval is deliberately narrow.
What it is
Bremelanotide is a synthetic cyclic peptide of seven amino acids. According to its FDA label it activates several melanocortin receptors, most strongly MC1R and then MC4R. MC4R sits on nerve cells across the brain; MC1R sits on pigment cells, which is why skin darkening is a known side effect. The label states plainly that how it affects sexual desire is unknown.
It came out of melanocortin research sparked by the finding that MT-2 caused erections. Early clinical work used a nasal form and included phase 2 trials in men with erectile dysfunction.
What the trials found
The approval rests on RECONNECT, two identical phase 3 trials published in Obstetrics & Gynecology in 2019. They randomised 1,267 premenopausal women with hypoactive sexual desire disorder (HSDD) to bremelanotide or placebo for 24 weeks. Both trials showed statistically significant gains in desire scores and drops in distress about low desire.
Side effects were common. The label reports nausea in 40% of patients, a short rise in blood pressure with a dip in heart rate after each dose, and darkened patches of skin in about 1%. Far more women quit on the drug than on placebo: 40% versus 13% in one trial.
Where the evidence stops
The label limits it to premenopausal women with acquired, generalised HSDD. It is not indicated for postmenopausal women or men, and not to enhance sexual performance. The trial gains were modest, and the published work in men we found stopped at phase 2. None of it covers research-grade material.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water goes in, it belongs in the fridge. Our reconstitution and storage guide covers the details, and the calculator does the maths.
A real approved drug with a narrow label, modest trial gains and a lot of nausea. The data stops at premenopausal women.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered PT-141 (Bremelanotide)
No reviews from orders with PT-141 (Bremelanotide) yet. Here is what recent customers said about ordering from us.
★★★★★
Communication with your team was quick and fast and the delivery was sooner than expected. Well done!
Sarel M. · 8 Oct 2026
★★★★★
The best service from start of order to delivery, and definitely the products are the best of the best! Im hooked!
Shannon O. · 8 Oct 2026
★★★★★
Youre the best Thankyou!!
Rosemary V. · 8 Oct 2026
★ 4.8 across all 21 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
